Dergiler / Marmara Medical Journal / 2026 / Volume: 39 Issue: 3

Complete response to fourth-line nivolumab in metastatic hepatocellular carcinoma: A case report

Sayfa
—
Yayın Tarihi
2026-10-28
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

This case demonstrates the potential of achieving exceptional and durable efficacy with nivolumab monotherapy in advanced HCC, even in patients previously treated with several lines of systemic treatment.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Hepatocellular carcinoma (HCC) is an important cause of cancer-related mortality, and systemic therapies have historically provided only limited benefit.
📊
Temel Bulgular & Veri:While immune checkpoint inhibitors (ICIs) have reshaped treatment strategies in HCC, durable complete responses with nivolumab monotherapy are rare.
💡
Sonuç & Katkı:This case demonstrates the potential of achieving exceptional and durable efficacy with nivolumab monotherapy in advanced HCC, even in patients previously treated with several lines of systemic treatment.
🔬Tür:Case Report
📍Kapsam:2019 Verileri
⚙️Değişkenler:Hepatocellular carcinoma · nivolumab · complete response

Abstract

Hepatocellular carcinoma (HCC) is an important cause of cancer-related mortality, and systemic therapies have historically provided only limited benefit. While immune checkpoint inhibitors (ICIs) have reshaped treatment strategies in HCC, durable complete responses with nivolumab monotherapy are rare. We describe a 71-year-old male with HCC related to hepatitis B virus (HBV) who failed multiple systemic therapies including capecitabine, sorafenib, and regorafenib. Nivolumab was initiated in December 2019, and complete remission was achieved within three months of treatment. The patient maintained a complete response for over six years without significant immune-related toxicity. This case demonstrates the potential of achieving exceptional and durable efficacy with nivolumab monotherapy in advanced HCC, even in patients previously treated with several lines of systemic treatment.

🔖

Bu Makaleye Atıf Yap

Apaydın, D., Güren, A. K., Köstek, O., Demircan, N. C. (2026). Complete response to fourth-line nivolumab in metastatic hepatocellular carcinoma: A case report. Marmara Medical Journal, Volume: 39 Issue: 3. https://doi.org/10.5472/marumj.2071755

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (14)

  1. Nagaraju GP, Dariya B, Kasa P, Peela S, El-Rayes BF. Epigenetics in hepatocellular carcinoma. Semin Cancer Biol 2022;86(Pt 3):622-32. doi: 10.1016/j.semcancer.2021.07.017.
  2. Brown ZJ, Tsilimigras DI, Ruff SM, et al. Management of Hepatocellular Carcinoma: A Review. JAMA Surg 2023;158:410-20. doi: 10.1001/jamasurg.2022.7989.
  3. Shen KY, Zhu Y, Xie SZ, Qin LX. Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives. J Hematol Oncol 2024;17:25. doi: 10.1186/s13045-024-01549-2.
  4. Chiew Woon L, Joycelyn Jie Xin L, Su Pin C. Nivolumab for the treatment of hepatocellular carcinoma. Expert Opin Biol Ther 2020;20:687-93. doi: 10.1080/14712598.2020.1749593.
  5. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389(10088):2492-502. doi: 10.1016/S0140-6736(17)31046-2.
  6. Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol 2022;23:77-90. doi: 10.1016/S1470-2045(21)00604-5.
  7. Yau T, Galle PR, Decaens T, et al. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial. Lancet 2025;405(10492):1851-64. doi: 10.1016/S0140-6736(25)00403-9.
  8. Han JE, Cho HJ, Kim SS, Cheong JY. Infiltrative hepatocellular carcinoma with multiple lung metastasis completely cured using nivolumab: a case report. J Liver Cancer 2021;21:169-76. 10.1186/s12885-020-07490-w
  9. Chen C-Y, Bal L-Y. Long-term remission by nivolumab monotherapy for sorafenib-refractory hepatocellular carcinoma. J Cancer Res Pract 2022;9:41-4. 10.4103/JCRP.JCRP_33_21
  10. Mendes JL, Spencer AS, Pimentel JC, et al. Five-year sustained response to nivolumab in hepatocellular carcinoma following serious ımmune-related hepatitis. GE Port J Gastroenterol 2024;32:306-13. doi:10.1159/000543288
  11. De Wilde N, Vonghia L, Francque S, et al. Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma. World J Hepatol 2022;14:1608-20. 10.4254/wjh.v14.i8.1608
  12. Doroshow DB, Bhalla S, Beasley MB, et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nat Rev Clin Oncol 2021;18:345-62. doi: 10.1038/s41571-021-00473-5.
  13. Hao L, Li S, Deng J, et al. The current status and future of PD-L1 in liver cancer. Front Immunol 2023;14:1323581. doi: 10.3389/fimmu.2023.1323581.
  14. El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 2017;389(10088):2492-502. doi: 10.1016/S0140-6736(17)31046-2.